Life Chemicals Inc.,  a leading provider of screening libraries and medicinal chemistry services and  Kineta, Inc. a biotechnology company focused on the development of novel modulating drugs for critical disease areas, today are happy to announce their participation in the KPI Therapeutics project.

Both Life Chemicals Inc. and Kineta, Inc. as well as other three participants (Chimera Biotec GmbH, MPI Research and Medical Marketing Economics) are embarked on a strategy to increase their range of new and exciting products and technologies such that this partnership makes good strategic sense. The agreement between the parties provides for the exclusive supply of products by Life Chemicals. All the companies wish to collaborate in order to further grow their differentiated technology and service offerings within the life sciences sector.

Dr. Volodymyr Fetyukhin, President of Life Chemicals, cited the reduction of research and development at large pharmaceutical companies as a compelling opportunity for new drug development models like KPI. "With the growing urgency for more effective medicine, there is no better time to maximize the efforts of committed partners to identify, develop, and keep developing a pipeline of commercially attractive, diversified early stage products for new therapies," said Dr. Fetyukhin. "We are sure that our experience in medicinal and synthetic chemistry will contribute to the overall success of this partnership, and I am very excited about seeing compounds we have synthesized in action."

For the details visit the link.